Recombinant Soluble Human FcγRII: Production, Characterization, and Inhibition of the Arthus Reaction

By F. L. Ierino, M. S. Powell, I. F. C. McKenzie, and P. M. Hogarth

From The Austin Research Institute, Austin Hospital, Heidelberg, Victoria 3084, Australia

Summary

A recombinant soluble form of human FcγRII (rsFcγRII) was genetically engineered by the insertion of a termination codon 5' of sequences encoding the transmembrane domain of a human FcγRII cDNA. Chinese hamster ovary cells were transfected with the modified cDNA and the secreted rsFcγRII purified from the tissue culture supernatant (to >95%, assessed by SDS-PAGE) using heat aggregated human immunoglobulin G (IgG) immunoaffinity chromatography. The IgG-purified rsFcγRII was relatively homogeneous (~31,000 M₉) whereas the total unpurified rsFcγRII secreted into the tissue culture supernatant was heterogeneous relating to N-linked glycosylation differences. Functional in vitro activity of the rsFcγRII was demonstrated by: (a) ability to bind via the Fc portion of human IgG and mouse IgG (IgG2a>IgG1>>IgG2b); (b) complete inhibition of binding of erythrocytes sensitized with rabbit IgG to membrane-bound FcγRII on K562 cells; and (c) inhibition of the anti-Leu4-induced T cell proliferation assay. Blood clearance and biodistribution studies show the rsFcγRII was excreted predominantly through the kidney in a biphasic manner, with an α-phase (t₁/₂ ~25 min) and a β-phase (t₁/₂ ~4.6 h); the kidneys were the only organs noted with tissue-specific accumulation. In vivo, the administration of rsFcγRII significantly inhibited the immune complex-mediated inflammatory response induced by the reversed passive Arthus reaction model in rats. There was a specific and dose-dependent relationship between the amount of rsFcγRII administered, and the reduction in the size and severity of the macroscopic inflammatory lesion. Histological analysis of the skin showed a diffuse neutrophil infiltrate in both control and rsFcγRII-treated rats, however the perivascular infiltrate and the red cell extravasation was less intense in the rsFcγRII-treated group. It is likely that complement activation leads to neutrophil chemotaxis, but neutrophil activation via FcγRII, which results in inflammatory mediator release, is inhibited. The data indicate that rsFcγRII is a potential therapeutic agent for the treatment of antibody or immune complex-mediated tissue damage.

Fc receptors for IgG (FcγR) exist in two forms: membrane-bound FcγR and soluble FcγR (sFcγR) which circulate in biological fluids. The two forms of FcγRs have been described in both human and murine systems, and have a central role in the regulation of the immune response (1). Membrane-bound human FcγRs are widely expressed on hemopoietic cells and can be divided into three major classes on the basis of their structure and affinity for IgG: FcγRI, FcγRII, and FcγRIII (2, 3). FcγRs are important signal transduction molecules, and the interaction of immune complexes through the Fc portion of IgG or mAbs with cell surface FcγRs triggers the activation of monocytes, neutrophils, and platelets (4–15). The binding of immune complexes to monocytes and neutrophils stimulates the release of inflammatory mediators such as leukotrienes, prostaglandins, and cytokines (TNF-α, IL-1, and IL-6), inducing tissue damage (16–22). Although the exact role of the FcγR(s) in mediating each of these effects has not been fully determined, human FcγRII has been definitively shown to signal immune complex-mediated activation of neutrophils and monocytes. In addition, platelets interact with immune complexes by cell surface FcγRII (the only FcγR expressed on platelets), leading to the secretion of mediators and platelet aggregation (8–15). Endogenous and recombinant sFcγR have been shown to have both in vitro and in vivo immunoregulatory activity.
and functional properties (23-32). In vitro, endogenous sFγR are released from cells expressing membrane-bound FγR: activated T cells, B cells, macrophages, monocytes, and granulocytes (33-39). Soluble FγR can be released by proteolysis of membrane-bound FγR (28, 29, 33), or possibly by alternative RNA splicing of the transmembrane exon (40), and can be stimulated by Ig and cytokines (1). Endogenous mouse sFγR has a relative molecular mass of 35-40 kDa and reacts with an anti–mouse FγRII mAb, 2.4G2. This antigenic similarity provides further evidence that endogenous sFγRII and membrane-bound FγRII are structurally related (41). In vitro, murine sFγRII can modulate the immune response by inhibition of four separate pathways: (a) binding of immune complexes to cell surface FγRII; (b) C1q binding to IgG; (c) B cell growth; and (d) IgG and IgM antibody production from B cells (1, 23-29). Endogenous murine sFγRII can be detected in serum of normal mice, and is elevated in states of altered immunity and tumor-bearing mice, indicating it may have an important biological role in vivo (36, 42-46). Supporting this concept, recombinant sFγRII has been demonstrated to inhibit the in vivo IgG response in mice (29). Similarly in humans, sFγRII can be detected in vivo from serum of normal individuals and patients with autoimmune diseases, and at sites of inflammation (47-49). The immunosuppressive properties of sFγRII and its potential ability to inhibit membrane-bound FγRII-mediated cellular activation by immune complexes, opens new therapeutic pathways for the treatment of antibody or immune complex–mediated tissue injury. This study describes the production, characterization, in vitro and in vivo activity of a human rsFγRII.

Materials and Methods

Genetic Engineering and Production of rsFγRII. Using the PCR, cDNA for a truncated soluble form of human FγRII was produced by inserting a premature termination codon 5' of the transmembrane domain of a membrane-bound FγRII cDNA (HFc3.0) (50). The HFc3.0 cDNA encodes the FγRIIa allele variant expressing glutamine and histidine at amino acid positions 27 and 131, respectively. The oligonucleotide primers used in the PCR were 5' oligonucleotide, NR1 ('5'TACGAATTCCTATGGAGACGCTCCAC3'), and 3' oligonucleotide, F12 ('5'CATTCTAGACTATTGGACAGTGATGGTCAC3'). Both oligonucleotide primers were phosphorylated (100 ng primer, 2 μl 10 mM ATP, 50 mM Tris-HCl, pH 7.6, 10 mM MgCl₂, 5 mM dithiothreitol, 0.1 mM EDTA, 80 U polynucleotide kinase [Pharmacia, Uppsala, Sweden], in 200 μl, incubated for 1 h at 37°C) and used to amplify the mutated cDNA (100 ng of membrane-bound FγRII cDNA HFc3.0, 500 ng of primers, 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl₂, and 2.5 U Uplinkase [Du Pont, Boston, MA]) with a 30 cycle PCR. The oligonucleotide F12 converted the mutated cDNA into a truncated soluble form of human FγRII. The sample was loaded onto an affinity column containing heat aggregated human IgG (Sandoz, Melbourne, Australia) and the bound human IgG was eluted with a 0.1 M acetic acid buffer, pH 4.0, containing 0.5 M NaCl. The eluant was further neutralized with saturated Triton-X-100 and dialyzed against PBS. The molecular weight and purity of the rsFγRII were determined by SDS-PAGE analysis. The protein content of the purified samples was determined by absorbance at 280 nm using an extinction coefficient of ε₂₈₀ = 22 000 M⁻¹ cm⁻¹ for recombinant human FγRII.

Biosynthetic Labeling and Deglycosylation of the rsFγRII. De-glycosylated recombinant protein was produced by adding 5 μg/ml tunicamycin (Sigma Chemical Co.) to the secreting transfected CHO cells for 2 h at 37°C; control transfected cells were grown in the absence of tunicamycin. Both control and tunicamycin-treated cells were pulsed with 0.5 mCi of [³⁵S]methionine and [³⁴C]cysteine (Amersham International, Amersham, UK) in glutamine/methionine/cysteine free medium (Select-Amine; GIBCO BRL, Gaithersburg, MD) followed by a 2-h incubation in the presence of 100-fold excess cold methionine/cysteine. Metabolically labeled supernatants from tunicamycin-treated and untreated transfected cells were precloned for 30 min at 4°C with packed Sepharose 4B beads coupled to protein A (Pharmacia) and immunoprecipitation (using 1 ml of radiolabeled supernatant per ml) carried out for 1 h at 4°C with 30 μl of packed Sepharose 4B beads conjugated to the following mAbs: (a) anti-FcyRII mAbs, 8.26 F(ab')₂, 8.2 F(ab')₂, 8.7 F(ab')₂, IV.3 F(ab')₂, and CIKM5 F(ab')₂; a control mAb, 1705 (5084-4.1) F(ab')₂, 8.7 F(ab')₂, IV.3 F(ab')₂, and CIKM5 F(ab')₂, were used with supernatant from transfected cells grown in the absence of tunicamycin; and (b) mAb 8.26 was used to immunoprecipitate from supernatant harvested from transfected CHO cells treated with tunicamycin (53-56). The beads were washed with a buffer containing PBS, 1% BSA, 1 mM PMSF, and 0.1% vol/vol aprotinin, pH 7.4 (Sigma Chemical Co.), placed in 20 μl of SDS-PAGE sample buffer (0.1 M Tris-HCl, pH 7.5, 0.1% SDS, 0.1 M dithiothreitol), boiled for 5 min, analyzed by SDS-PAGE on a 13% gel which was dried and autoradiographed.
Immunoprecipitation and SDS-PAGE Analysis. Purified rsFcγRII (100 μg) was radiolabeled with 125I (Amersham International) using chloramine T (57). The rsFcγRII was diluted to 0.2 μg/ml in a buffer containing PBS, 1% BSA, 1mM PMSF, and 0.1% vol/vol aprotinin, pH 7.4, preclarred, and immunoprecipitation (0.2 μg of labeled rsFcγRII per antibody) was carried out as described above with 30 μl of packed Sepharose 4B beads conjugated to the following antibodies: (a) anti-human FcγRII mAb, 8.26 F(ab)'; (b) control antibody, 1705 F(ab)'; mouse IgG2a anti-Ly-12.1; (c) whole mouse IgG1, 1-1 anti-CEA; (d) whole mouse IgG2a 1302 (49-11.1), anti-Ly-2.1; (e) whole mouse IgG2b 1480 (5041-24.2), anti-Ly-6A.2; (f) whole mouse IgG3, 1308 (49-31.1), anti-Ly-2.1; and (g) HAGG (53, 56, 58-60).

Erythrocytes Sensitized with Rabbit IgG (EA) Rosetting Inhibition Assays. The ability of the rsFcγRII to block the binding immune complexes to membrane-bound FcγRII was determined by the inhibition of EA rosette formation. Starting at a final concentration of 0.4 mg/ml, doubling dilutions of the purified rsFcγRII or a control protein, OVA, were incubated with 50 μl of freshly prepared 2% EA (rabbit anti-sheep red cell polyclonal antibody diluted 1:50 bound to sheep red cells) for 1 h on ice (61). K562 cells (25 μl at 5 × 105 cells/ml) expressing FcγRII were added to the EAs and rsFcγRII, incubated for 5 min at 37°C, spun at 200 g for 3 min, and the pelleted cells incubated for 30 min on ice. Cells were stained with 0.1% ethyl violet and a typical field of 100 cells was assessed for rosette formation (at least five red cells or 50% of the target cell covered).

Inhibition of the Anti-Leu4-induced T Cell Proliferation Assay by rsFcγRII. In this assay, T cells coated with anti-CD3 antibody can be cross-linked via the Fc portion, by the FcγR on monocytes (62, 63). This phenomenon can be inhibited by rsFcγRII. PBMC from an individual were isolated using a Ficoll density gradient (Pharmacia), harvested, washed, and resuspended in RPMI 1640 (Flow Laboratories) supplemented with 10% heat inactivated FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine (Commonwealth Serum Laboratories) and 0.05 mM 2-ME (Kock-Light Ltd., Suffolk, UK) at 5 × 105 cells/ml. Cells (300 μl vol) were aliquoted into U-bottomed sterile 96-well microtiter plates (Nunc, Roskilde, Denmark) and incubated with 50 μl of freshly prepared rabbit anti-Leu4 (Becton Dickinson & Co., Mountain View, CA) at 1:1,000 dilution and 50 μl of serially diluted rsFcγRII or control protein, OVA, starting at 1.0 mg/ml final concentration. Incubation was carried out for 72 h at 37°C, and after the last 14 h cells were pulsed with 1 μCi/well [3H]thymidine (3,000 Ci/mol, Amersham International), harvested, and assayed for completion in a radiometric counter (1705). The results were expressed as percent inhibition compared to control wells.

Production and Purification of rsFcγRII. The rsFcγRII cDNA construct was transfected into CHO cells and resulted in a soluble recombinant protein that was secreted into the cell culture supernatant. Maximally expressing amplified transfected CHO cells (Clone 1.5) were grown in 100 μM MSX and produced 4–8 μg of purified rsFcγRII per ml of cell culture supernatant. Immunoadfinity purification using human IgG Fc binding utilized the natural physiological ligand for the receptor and gentle elution conditions enabled maximal yield, with minimal loss of Fc binding capacity of the recombinant protein. An eluted sample analyzed by SDS-PAGE is shown (Fig. 1) and appears as a ∼31,000 M, band consistent with the urinary excretion of the injected dose.

Arthus Reaction. A modified reversed passive Arthus reaction (RPAR) model (65) was established using 4–6-wk-old Sprague-Dawley rats (Austin Research Institute) anesthetized with an i.p. injection of 1.5–2.0 ml of a 1.9% 2,2,2-tribromoethanol (Aldrich Chemical Co., Milwaukee, WI) solution. The rats were shaved, and 5 min after a 5 mg i.v. injection of OVA into the tail vein, the back of the rat was injected intradermally with either: (a) 50 μl of purified rabbit IgG anti-OVA (500 μg) with 50 μl of PBS, positive control (after titration, limiting amounts of rabbit IgG anti-OVA were used to give maximal inhibition, similar to that used elsewhere) (66); (b) 50 μl of purified nonimmune rabbit IgG (500 μg) with 50 μl of PBS, specificity control; (c) 50 μl of rabbit IgG anti-OVA (500 μg) with 50 μl of rsFcγRII at varying doses (50–500 μg) or control protein KLH (500 μg) (Sigma Chemical Co.); or (d) rsFcγRII alone.

Rats were examined at 6 h, and macroscopic skin lesions were analyzed (blind by independent observers) using two criteria: (a) size of the lesion; the area in mm2 was calculated by multiplying the transverse width in two perpendicular directions; and (b) "total score" reflecting the severity of each lesion; a minor score of 0 (nil), 1 (mild), 2 (moderate), or 3 (severe) was given for two separate parameters (edema and erythema), and a total score for the lesion was assigned by adding the two minor scores. Skin biopsies at injected sites, taken through the center of the lesion, were fixed in 10% buffered formalin, stained with hematoxylin-eosin (Department of Pathology, Austin Hospital) and examined for edema, polymorphonuclear, and mononuclear cell infiltrate.

Statistical Analysis. A statistical comparison of the size and scores of the rsFcγRII-treated skin and the controls (PBS and KLH treatment) was performed by a one-way analysis of variance (67); p <0.05 was considered significant.

Results

Production and Purification of rsFcγRII. The rsFcγRII cDNA construct was transfected into CHO cells and resulted in a soluble recombinant protein that was secreted into the cell culture supernatant. Maximally expressing amplified transfected CHO cells (Clone 1.5) were grown in 100 μM MSX and produced 4–8 μg of purified rsFcγRII per ml of cell culture supernatant. Immunoadfinity purification using human IgG Fc binding utilized the natural physiological ligand for the receptor and gentle elution conditions enabled maximal yield, with minimal loss of Fc binding capacity of the recombinant protein. An eluted sample analyzed by SDS-PAGE is shown (Fig. 1) and appears as a ∼31,000 M, band consistent with...
tent with the predicted 20,000 $M_r$ of the rsFcγRII polypeptide chain and the extra size from two N-linked carbohydrate structures. The rsFcγRII was >95% pure as analyzed by SDS-PAGE. The stability of the rsFcγRII in tissue culture supernatant was measured by the ELISA for FcγRII, and showed it was stable (mAb epitopes intact) at 4, -20, and -70°C for 6 mo. Functional activity of the rsFcγRII, demonstrated by inhibition of EA rosette formation, was completely stable for at least 1 mo at 4°C (data not shown).

**Structure of the Truncated FcγRII.** RsFcγRII was deglycosylated to determine the contribution of carbohydrate to the heterogeneity. Cell culture supernatant of clone 1.5 CHO cells biosynthetically labeled with [35S]methionine and cysteine was used for immunoprecipitation and the molecular weight of the deglycosylated polypeptide determined after growing the transfected CHO cells in tunicamycin. Immunoprecipitation with F(ab') or F(ab')2 fragments of specific anti-human FcγRII mAbs demonstrated that the total unpurified rsFcγRII in tissue culture supernatant was heterogeneous with ~28,000-36,000 $M_r$ (Fig. 2), whereas the IgG-purified rsFcγRII (Fig. 1) was more homogeneous. However, after tunicamycin treatment, a homogeneous ~23,000 $M_r$ band under reducing conditions (Fig. 2) and ~21,000 $M_r$ in nonreducing conditions (data not shown) was detected, which agrees with the predicted molecular mass of 20,000 and demonstrated that the heterogeneity of the total rsFcγRII protein was due to heterogeneity within the N-linked carbohydrate, rather than proteolytic degradation or partial translation of the mRNA. The five mAbs used (IV.3, CIKM5, 8.2, 8.7, and 8.26) (Fig. 2) previously have been shown to divide into four clusters, each cluster defining a separate epitope on the extracellular domains of FcγRII (53). Cluster 1 (8.2 and CIKM5) defines an epitope with determinants in both domains 1 and 2 of FcγRII and lies distant from the Fc binding region, and clusters 2 (8.26), 3 (IV.3), and 4 (8.7) detect three additional epitopes contained in the second extracellular domain only. All five mAbs recognize the heterogeneous glycosylated 31-kD rsFcγRII protein. Detection of the rsFcγRII by the mAbs, particularly mAbs from cluster 1 which define a combinatorial epitope, indicates that the

![Figure 2](image-url)  
**Figure 2.** Immunoprecipitation of the glycosylated and deglycosylated rsFcγRII analyzed on 13% SDS-PAGE gel under reducing conditions, with molecular weight markers (kD) on the left. Supernatant from [35S]methionine/cysteine-labeled transfected CHO cells were immunoprecipitated using: 1705 F(ab')2 control mAb (lane 1); IV.3 F(ab') mAb (lane 2), CIKM5 F(ab')2 mAb (lane 3), 8.2 F(ab')2 mAb (lane 4), 8.7 F(ab')2 mAb (lane 5), and 8.26 F(ab') mAb (lane 6). Immunoprecipitation from supernatant using tunicamycin-treated secreting CHO cells, with mAb 8.26 F(ab') is shown in lane 7.

![Figure 3](image-url)  
**Figure 3.** 13% SDS-PAGE analysis of immunoprecipitated [35S]-labeled rsFcγRII under reducing conditions using: mAb 8.26 F(ab') (lane 1); mAb 1705 F(ab')2 (lane 2); whole murine, IgG1 mAb I-1 (lane 3); IgG2a mAb 1302 (lane 4); IgG2b mAb 1480 (lane 5); IgG3 mAb 1308 (lane 6); and HAGG (lane 7). Molecular weight markers (kD) are indicated on the left.

![Figure 4](image-url)  
(A) Inhibition of EA rosette formation by rsFcγRII (sFc) using K562 FcγRII+ target cells; and (B) inhibition of the anti-Leu4-induced T cell proliferation assay using rsFcγRII (sFc) or control protein (OVA).
tertiary structure of rsFcγRII resembles that of the membrane-bound FcγRII. Since the ligand-purified rsFcγRII was homogeneous and functional, in that it was purified by IgG aggregates (Fig. 1), only this material was used for further studies.

*IgG Fc Binding by rsFcγRII.* The Fc binding capacity of the purified rsFcγRII was examined by 125I radiolabeling the rsFcγRII and immunopurification with HAGG or murine IgG1, IgG2a, IgG2b, and IgG3 mAbs; mAbs 8.26 F(ab')2 (positive control) and F(ab')2 fragments of 1705 (Fc binding specificity control) were included (Fig. 3). SDS-PAGE analysis revealed the same 31-kD protein with the anti-FcγRII mAb 8.26, murine IgG1, IgG2a, and HAGG. Binding to murine IgG2b was variable as no binding was detected using the IgG2b mAb, 1480 (Fig. 3), although another murine IgG2b mAb exhibited some binding (data not shown). There was very little binding to IgG3 and no binding to the F(ab')2 fragments of the nonreactive control mAb 1705 indicating that the binding of the purified rsFcγRII to IgG was specifically through the interaction of the Fc portion of IgG with the soluble receptor.

![Graph A](image-url)

![Graph B](image-url)

![Graph C](image-url)

**Figure 5.** Blood clearance and biodistribution of 125I-rsFcγRII. (A) Blood clearance of 125I-rsFcγRII; percent initial injected dose is shown on the y-axis and time (hours) on the x-axis. (B) Urine 125I-rsFcγRII levels, expressed as percent initial injected dose/ml of urine, at 15 min (n = 4) and 1 h (n = 2). (C) Biodistribution in various organs showing the percent initial injected dose/gram of tissue on the y-axis. Error bars, SE.
The murine IgG binding specificity of the rsFc3RII differs from the membrane-bound human FcγRII; rsFcγRII binds murine IgG2a>IgG1>>IgG2b, and IgG3. It should be noted that the HFc3.0 cDNA encodes a histidine at position 131 and poor immunoprecipitation with the murine IgG1 mAb seen in Fig. 3 would be expected as this is a "low responder" FcγRII (68–70).

The binding of rsFcγRII to immune complexes was demonstrated by its ability to inhibit the binding of EAs to cell surface FcγRII. Incubation of EAs with rsFcγRII completely inhibited the formation of EA rosettes with K562 cells, with a 50% inhibitory final concentration of 20 μg/ml of purified rsFcγRII (Fig. 4A). In addition, rsFcγRII inhibited the anti-Leu4–induced T cell proliferation assay by 50% at a final concentration of 125 μg/ml, indicating the soluble receptor has the capacity to block the binding of immune complexes to FcγRII on peripheral blood monocytes (Fig. 4B). We also tested the ability of rsFcγRII to inhibit an antibody-dependent, cell-mediated cytotoxicity assay and a C′-mediated cell lysis assay using rabbit C′ and a murine mAb. No inhibition was observed in either assay (data not shown).

In summary, the physical and functional characteristics of the rsFcγRII are similar to membrane-bound FcγRII: (a) rsFcγRII is structurally related to membrane-bound FcγRII as indicated by intact epitopes for the binding of mAbs to membrane-bound FcγRII; and (b) rsFcγRII binds IgG through its Fc region, although the murine isotope binding specificity has been altered compared to membrane-bound human FcγRII. It is noteworthy that the general characteristics of human FcγRII in relation to binding specificities of IgG have been derived from studies using few cell types and may not apply in all cases (2).

Blood Clearance and Biodistribution of rsFcγRII. The in vivo characteristics of rsFcγRII were studied in mice by analyzing the blood clearance and biodistribution of intravenously administered 125I-rsFcγRII. The blood clearance studies demonstrate that 125I-rsFcγRII is rapidly eliminated from the circulation in a biphasic manner with an α-phase t1/2 of 25 min and a β-phase t1/2 of 4.6 h; after 24 h the 125I-rsFcγRII was totally eliminated (Fig. 5A). Groups of four mice were also injected intravenously and various organs were counted for radioactivity (Fig. 5C). There was a rapid early concentration of 125I-rsFcγRII in the kidney at 15 min and 1 h, with a subsequent fall at 6 and 24 h. No other organ exhibited tissue-specific accumulation. The rapid clearance from the circulation, associated with high concentrations in the kidney, suggested the recombinant protein was excreted predominantly through the kidney. Studies of urine demonstrate high levels of 125I-rsFcγRII at 1 h, indicating this to be the major route of excretion (Fig. 5B). The effect of route of administration was studied by giving either an i.p. or i.v. dose of 125I-rsFcγRII. An identical pattern of rapid blood clearance was seen with both i.p. and i.v. injections (data not shown).

Inhibition of the Arthus Reaction. Rats given i.v. OVA (5 mg) followed by intradermal rabbit anti-OVA IgG (500 μg) mixed in PBS developed a visible Arthus reaction within 2 h of the intradermal injection and at 6 h were characterized macroscopically by an erythematous and edematous area of skin measuring 30 mm² determined from the width of the lesion in two perpendicular transverse directions (Fig. 6). Histologically, the tissue section from the site of the lesion showed an inflammatory infiltrate of polymorphonuclear cells, and to a lesser extent mononuclear cells, particularly around vessels in the dermis (Fig. 7). Specificity of the RPAR was demonstrated by giving rats i.v. OVA, intradermal rabbit IgG, or rsFcγRII, all given separately to individual rats, or nonimmune rabbit IgG intradermally together with i.v. OVA. In all cases, the RPAR did not develop (data not shown).

To test the effect of rsFcγRII, OVA-injected rats were then given a constant amount of rabbit anti-OVA IgG (500 μg) mixed with rsFcγRII at varying doses (50–500 μg) in a final volume of 100 μl intradermally. When rsFcγRII was given with the rabbit anti-OVA IgG, a specific and significant dose-dependent inhibition of the size (using 500 μg of rsFcγRII, p <0.05) and the score (using 500 and 150 μg of rsFcγRII, p <0.05) was noted.

![Figure 6](image-url)
Figure 7. Histology of the Arthus reaction in skin, treated with PBS (positive control) 6 h after injection, showing intense perivascular neutrophil infiltrate. ×100.

Figure 8. Histology of the PBS-treated skin demonstrating a typical perivascular neutrophil infiltrate with extravasation of erythrocytes. ×400.
both \( p < 0.05 \) of the Arthus lesion was observed, compared to PBS- and KLH (irrelevant protein control)-treated lesions (Fig. 6). The results represent multiple injections using a number of different rats. Histological sections taken from the sites treated with the rsFcyRII mixed with the rabbit anti-OVA showed a marked reduction in neutrophil accumulation, margination, infiltration around venules, and erythrocyte extravasation compared to PBS-treated skin (Figs. 7-9). The mild, persistent neutrophil infiltrate in the rsFcyRII-treated skin is likely to be a consequence of the short \( t_1/2 \) of rsFcyRII and C activation.

Discussion

A functional rsFcyRII protein was made by genetically deleting the transmembrane and cytoplasmic domains of a human FcyRII protein, and using a novel eukaryotic expression system in CHO cells, resulted in the secretion of the rsFcyRII into the tissue culture supernatant, enabling subsequent purification. The recombinant glycoprotein was shown to have in vitro and in vivo activity. The truncated 31-kD recombinant protein containing the two extracellular domains of FcyRII could bind human, mouse, and rabbit Ig by their Fc portions, and completely inhibited the binding of immune complexes to cell surface FcyRII. The interaction of immune complexes with cell surface FcyRII initiates a number of Fc-mediated effector mechanisms including inflammatory responses, and therefore, a classical model of immune complex disease (the Arthus reaction) was used to investigate the possible in vivo therapeutic properties of the human rsFcyRII. The RPAR was significantly inhibited by rsFcyRII in a dose-dependent manner, with less extensive macroscopic lesions and histological inflammatory cell infiltrates demonstrated in treated areas.

The first part of the study addressed the problem of producing large quantities of purified functional rsFcyRII. The mammalian expression vector, pEE6/CMV/GS, was utilized as it gives high levels of expression (51). In this study, all the original clones did not survive in >15 \( \mu \)M MSX, although amplification of the initial clones using 100-1,000 \( \mu \)M MSX produced survivors in 100 \( \mu \)M MSX, and a fourfold increase in rsFcyRII production was noted in the amplified clones (4–8 mg/liter of supernatant). This could be increased by further selection and attention to the culture medium, however the production level sufficed for our studies. Kinetic studies (data not shown) using supernatant and cell lysates from biosynthetically labeled transfected CHO cells was performed to exclude the possibility of a defective secretory mechanism resulting in intracellular accumulation of rsFcyRII. These studies demonstrated that the synthesized rsFcyRII first appeared in the tissue culture supernatant within 1 h of the initial \( ^{35} \)S-methionine/cysteine pulse and was totally secreted in 2 h, with no intracellular accumulation.

RsFcyRII is a functional receptor and clearly binds IgG

Figure 9. Histology of rat skin treated with 500 \( \mu \)g of rsFcyRII showing reduction in the inflammatory reaction. \( \times 100 \).
through the Fc portion, albeit with altered properties compared to the native cell surface FcγRII. Membrane-bound human FcγRIIa is a low affinity receptor (Kd = 10^6 M⁻¹) for monomeric IgG, and the low responder form binds murine IgG2b>IgG2a,IgG3 compared to rsFcγRII which binds murine IgG2a>IgG1>>IgG2b, or IgG3 (Fig. 3). The poor binding of rsFcγRII to murine IgG1 is consistent with the "low responder" phenotype which is a genetically determined polymorphism resulting in the expression of two allelic variants which differ in their ability to bind murine IgG1; high responders bind murine IgG1 more avidly than low responders (62, 63). Low responder FcγRII, like HFC3.0 used herein, contains histidine at position 131 whereas high responder FcγRII contains arginine in this position (68-70). Furthermore, some changes in fine specificity may not be unexpected since significant changes in carbohydrate side chains from the native receptor could alter the conformation and therefore the binding properties, as reported for other receptors (71). This may account for the difference in IgG2a and IgG2b binding reported here and in the literature. The absence of the transmembrane and cytoplasmic tail may also influence structural and functional aspects of the soluble receptor, however, the essential properties have been maintained since the rsFcγRII binds IgG via the Fc portion and is recognized by mAbs which detect conformational changes in cell surface FcγRII.

RsFcγRII is a relatively small polypeptide (31,000 Mw) with ~25% of its molecular mass attributable to N-linked glycosylation. Small molecular weight compounds would be expected to be easily filtered through the glomerulus and indeed, the rsFcγRII is rapidly cleared from the circulation through the kidneys (Fig. 5). One might expect a longer in vivo half-life if rsFcγRII bound to IgG in serum, however several factors may influence this interaction: (a) rapid renal clearance not allowing the rsFcγRII–IgG interaction to approach equilibrium in serum; and (b) affinity of monomeric IgG for rsFcγRII. The short half-life of the rsFcγRII in vivo will clearly limit the use of the protein as a parenterally administered therapeutic agent, but in its present form, could be useful for local therapy such as in inflamed joints in rheumatoid arthritis. The RPAR model used in this study produced a localized area of dermal inflammation and demonstrates that rsFcγRII administered concomitantly with anti-OVA antibody significantly reduces the immune complex-mediated tissue damage. Many cytokines with rapid clearance from the circulation, resulting in short-lived pharmacological effects, have been successfully modified to increase their half-life and subsequent potency of the compound in vivo (72-73). A similar approach with the rsFcγRII protein (currently in progress) would broaden its therapeutic application to a parenterally administered reagent.

In two other reports (66, 74) C' regulating proteins (soluble C receptor type I and decay accelerating factor) did not completely inhibit the Arthus reaction. In one study, the RPAR model used was similar to that used here (66). The persisting inflammatory response seen after treatment with the C' regulators is likely to be due to "unblocked" FcγR-mediated inflammatory response. Similarly, in the study described herein, inhibition of the inflammatory response was profound but incomplete. This probably relates to the short t½ and/or inability to inhibit C' activation. Since both FcγR- and C'-mediated inflammatory responses are critical in the pathogenesis of immune complex-induced tissue injury, complete inhibition of the inflammatory response presumably requires inhibition of both pathways. Studies are currently in progress to determine the potency of "combined" therapy.

The mode of action of rsFcγRII is not clear but could be mediating the anti-inflammatory response by several different mechanisms. One likely site of inhibition is the activation of neutrophils and monocytes with subsequent release of inflammatory mediators which is known to be signaled through the interaction of immune complexes with cell surface FcγRII, and we have shown in this study that rsFcγRII completely inhibits the binding of EA immune complexes to cell surface FcγRII and furthermore inhibits the anti-Leu4-induced T cell proliferation assay which results from the binding of rsFcγRII to the Fc portion of anti-Leu4 bound to T cells (Fig. 4). A second possible mechanism is the interruption of the C' cascade known to release many inflammatory proteins (e.g., C5a) which induce chemotaxis and neutrophil activation. Murine soluble FcγRII has been shown to inhibit C'-mediated lysis of SRBC by IgG in vitro (24). We found that rsFcγRII did not inhibit C'-mediated cell lysis or antibody-dependent cell-mediated killing by mononuclear cells. Antibody-dependent cell-mediated lysis is a function of FcγRIII, and therefore inhibition by rsFcγRII was not expected. It is likely that complement is activated, which leads to neutrophil chemotaxis, but neutrophil activation via FcγRII by immune complexes, which results in inflammatory mediator release, is inhibited. Platelets have been shown to initiate or augment immunologically mediated inflammation and tissue injury by the activation of circulating platelets through the interaction of immune complexes with cell surface FcγRII (8). Inhibition of platelet activation and aggregation could also reduce the inflammatory response, and we are currently investigating the role of rsFcγRII in modifying platelet function.

We thank Dr. J. Gorman of the Commonwealth Scientific and Industrial Research Organisation, Division of Biomolecular Engineering (Parkville, Victoria, Australia) for the amino acid analysis of the recombinant soluble FcγRII protein. We also thank Ms. T. Athanasiadis for secretarial assistance.

This work was supported by the National Health and Medical Research Council of Australia and The Helen Schutt Foundation.
References

1. Fridman, W.H., and C. Sautes. 1990. Immunoglobulin binding factors. In Fc Receptors and the Actions of Antibodies. H. Metzger, editor. American Society for Microbiology, Washington, DC. 335 pp.

2. Van De Winkel, J.G.J., and C.L. Anderson. 1991. Biology of human immunoglobulin G Fc receptors. J. Leukocyte Biol. 49:511.

3. Ravetch, J.V., and J.-P. Kinet. 1991. Fc receptors. Annu. Rev. Immunol. 9:457.

4. Macintyre, E.A., J.P. Roberts, R. Abdul-Gaffar, K. O’Flynn, G.R. Pilkington, F. Parace, J. Morgan, and D.C. Lynch. 1988. Mechanism of human monocyte activation via the 40-kDa Fc receptor for IgG. J. Immunol. 141:4333.

5. Van De Winkel, J.G.J., W.J.M. Tax, C.W.M. Jacobs, T.W.J. Huizinga, and F.H.G.M. Willems. 1990. Cross-linking of both types of IgG Fc receptors, FcγRI and FcγRII, enhances intracellular free Ca2+ in the monocyte cell line U937. Scand. J. Immunol. 31:315.

6. Huizinga, T.W.J., F. Van Kemenade, L. Koenderman, K.M. Abraham, and C.L. Anderson. 1985. Human platelets Fc receptor: identification as 40,000 molecular weight membrane protein shared by monocytes. J. Clin. Invest. 60:1272.

7. Willis, H.E., B. Browder, A.J. Feister, T. Mohanakumar, and S. Ruddy. 1988. Monoclonal antibody to human IgG Fc receptors: cross-linking of receptors induces lysosomal enzyme release and superoxide generation by neutrophils. J. Immunol. 140:234.

8. Henson, P.M., and M.H. Ginsberg. 1981. Immunological reactions of platelets. In Platelets in Biology and Pathology. J.L. Gordon, editor. Elsevier/North Holland Biomedical Press, Amersham. 265 pp.

9. Phueller, S.L., and E.F. Luscher. 1972. The effects of aggregated immunoglobulin on human blood platelets in relation to their complement fixing abilities. I. Studies of immunoglobulin of different types. J. Immunol. 109:517.

10. Henson, P.M., and H.L. Speigelberg. 1973. Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and subclasses. J. Clin. Invest. 52:1282.

11. Martin, S.E., R.T. Breckenridge, S.I. Rosenfeld, and J.P. Leddy. 1978. Response of human platelets to immunoglobulin stimuli: independent roles for complement and IgG in zymosan activation. J. Immunol. 120:9.

12. Karas, S.P., W.F. Rosse, and R.J. Kuriander. 1982. Characterisation of the IgG Fc receptor on human platelets. Blood. 60:1272.

13. Rosenfeld, S.R., R.J. Looney, J.P. Leddy, D.C. Phipps, G.N. Abraham, and C.L. Anderson. 1985. Human platelets Fc receptor for immunoglobulin G: identification as 40,000 molecular weight membrane protein shared by monocytes. J. Clin. Invest. 76:2317.

14. Anderson, G.P., and C.L. Anderson. 1990. Signal transduction by the platelet Fc receptor. Blood. 76:1.

15. Slupsky, J.R., J.C. Cawley, L.S. Griffith, A.R.E. Shaw, and M. Zuzel. 1992. Role of FcγRII in platelet activation by monoclonal antibodies. J. Immunol. 148:3189.

16. Rouzer, C.A., W.A. Scott, A.L. Hamill, and Z.A. Cohn. 1980. Dynamics of leukotriene C production by macrophages. J. Exp. Med. 152:1236.

17. Rouzer, C.A., W.A. Scott, J. Kempe, and Z.A. Cohn. 1980. Prostaglandin synthesis by macrophages requires a specific receptor–ligand interaction. Proc. Natl. Acad. Sci. USA. 77:4279.

18. Cardella, C.J., P. Davies, and A.C. Allison. 1974. Immune complexes induce selective release of lysosomal hydrolases from macrophages. Nature (Lond.). 247:46.

19. Anegon, I., M.C. Cuturi, G. Trinchieri, and B. Perussia. 1988. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 16:452.

20. Debs, J.M.H., J.G.J. Van De Winkel, J.L. Cuppens, I.E.M. Dieteresen, and W.A. Buurman. 1990. Cross-linking of both FcγRI and FcγRII induces secretion of tumour necrosis factor by human monocytes, requiring high affinity Fc–FcγR interactions. J. Immunol. 144:1304.

21. Krutmann, J., R. Kirnbauer, A. Kock, T. Schwarz, E. Schopf, L.T. May, P.B. Sehgal, and T.A. Luger. 1990. Cross-linking Fc receptors on monocytes triggers IL-6 production. J. Immunol. 145:1337.

22. Remvig, L., B.S. Thomsen, L. Baek, M. Svenson, and K. Bendtzen. 1990. Interleukin 1, but not interleukin 1 inhibitor, is released from human monocytes by immune complexes. Scand. J. Immunol. 32:255.

23. Loury, I., C. Brezin, C. Neauport-Sautes, J. Theze, and W.H. Fridman. 1983. Isotype regulation of antibody production: T cell hybrids can be selectively induced to produce subclass specific suppressive immunoglobulin binding factors. Proc. Natl. Acad. Sci. USA. 80:2323.

24. Fridman, W.H., C. Rabourdin-Combe, C. Neauport-Sautes, and R.H. Gisler. 1981. Immunoregulatory role of T cell Fcγ receptors. Immunol. Rev. 56:51.

25. Gisler, R.H., and W.H. Fridman. 1975. Suppression of in vitro antibody synthesis by immunoglobulin binding factors. J. Exp. Med. 142:507.

26. Brunati, S., J. Moncuit, W.H. Fridman, and J.L. Telllaud. 1990. Regulation of IgG production by suppressor FcγRII+ T hybridomas. Eur. J. Immunol. 20:55.

27. Varin, N., C. Sautes, A. Galiha, J. Even, P.M. Hogarth, and W.H. Fridman. 1989. Recombinant soluble receptor for the FcγRII portion inhibits antibody production in vitro. Eur. J. Immunol. 19:2263.

28. Sautes, C., N. Varin, C. Teillaud, M. Daeron, J. Even, P.M. Hogarth, and W.H. Fridman. 1991. Soluble Fcγ receptor II (FcγRII) are generated by cleavage of membrane FcγRII. Eur. J. Immunol. 21:231.

29. Fridman, W.H., C. Bonnerot, M. Daeron, S. Amigorena, J. Teillaud, and C. Sautes. 1992. Structural bases of Fcγ receptor
functions. *Immunol. Rev.* 125:49.
30. Qu, Z., J. Odin, J.D. Glass, and J.C. Unkless. 1988. Expression and characterization of a truncated murine Fcy receptor. *J. Exp. Med.* 167:1195.
31. Ierino, F.L., M.S. Powell, I.F.C. McKenzie, and P.M. Hogarth. 1992. Functional recombinant soluble human FcγRII. *Transplant. Proc.* 24:2326.
32. Peltz, G.A., M.C. Trounstone, and K.W. Moore. 1988. Cloned and expressed human Fc receptor for IgG mediates anti-CD3 dependent lymphoproliferation. *J. Immunol.* 141:1891.
33. Sarmay, G., Z. Rozsnyay, and J. Gergely. 1990. FcRII expression and release on resting and activated human B lymphocytes. *Mol. Immunol.* 27:1195.
34. Fridman, W.H., and P. Goldstein. 1974. Immunoglobulin binding factor present on and produced by thymus processed lymphocytes (T-cells). *Cell. Immunol.* 11:442.
35. Fridman, W.H., C. Rabourdin-Combe, C. Neauport-Sautes, and R.H. Gisler. 1981. Immunoregulatory role of T cell Fcy receptors. *Immunol. Rev.* 56:51.
36. Pure, E., C.J. Durie, C.K. Summerill, and J.C. Unkeless. 1984. Identification of soluble Fc receptors in mouse serum and conditional medium of stimulated B cells. *J. Exp. Med.* 160:1836.
37. Calvo, C., F. Watanabe, D. Metivier, and A. Senik. 1986. Human monocyte cell line U937 releases suppressive IgG-Fc. *Eur. J. Immunol.* 16:25.
38. Bich Thay, L.T., C. Samarut, C. Rabourdin-Combe, and J.P. Taylor. 1984. Circulating cell-free Fc3,2b/3I, receptor in man as measured by 131I-tagged albumin. *J. Clin. Invest.* 73:47.
39. Baer, M., and E. Gehanno. 1985. Murine type II Fc receptors and IgG binding factors. *Eur. J. Immunol.* 16:1545.
40. Sautes, C., N. Varin, P.M. Hogarth, J.C. Unkeless, C. Teillaud, J. Even, A. Lynch, and W.H. Fridman. 1990. Molecular and functional studies of recombinant soluble Fcγ receptors. *Mol. Immunol.* 27:1201.
41. Khayat, D., D. Serban, Z. Dux, Y. Schlomo, and C. Jacquillat. 1986. Role of infection in the modulation of mouse circulating soluble cell-free Fcγb/γ1 receptor. *Scand. J. Immunol.* 24:83.
42. Khayat, D., Z. Dux, R. Anavi, Y. Schlomo, I.P. Witz, and M. Ran. 1984. Circulating cell-free Fcγb/γ1 receptor in normal mouse serum: its detection and specificity. *J. Immunol.* 123:2496.
43. Lynch, A., E. Tartour, J.L. Teillaud, B. Asselin, W.H. Fridman, and C. Sautes. 1992. Increased levels of soluble low affinity Fcγ receptors (IgG-binding factors) in the sera of tumour-bearing mice. *Clin. Exp. Immunol.* 87:208.
44. Daeron, M., C. Sautes, C. Bonnerot, U. Blank, N. Varin, J. Even, P.M. Hogarth, and W.H. Fridman. 1989. Murine type II Fc γ receptors and IgG-binding factors. *Chem. Immunol.* 47:21.
45. Khayat, D., C. Geffrier, S. Yoon, E. Scigliano, C. Soubran, M. Weil, and J. Unkeless. 1987. Soluble circulating Fcγ receptor in human serum, a new ELISA for specific quantitative detection. *J. Immunol.* 100:235.
46. Fleit, H.B., C.D. Kobasiuk, C. Daly, R. Furie, P.C. Levy, and R.D. Webster. 1992. A soluble form of FcγRIII is present in human serum and other body fluids and is elevated at sites of inflammation. *Blood.* 79:2721.
47. Huizinga, T.W.J., M. De Haas, M. Kleijer, J.H. Nuijens, D. Roos, and A.E.G. Kr Von Dem Borne. 1990. Soluble FcγRIII in human plasma originates from release by neutrophils. *J. Clin. Invest.* 86:416.
48. Hibbs, M., L. Bonadonna, B.M. Scott, I.F.C. McKenzie, and P.M. Hogarth. 1988. Molecular cloning of a human immunoglobulin G Fc receptor. *Proc. Natl. Acad. Sci. USA.* 85:2240.
49. Davis, S.J., H.A. Ward, M.J. Puklavec, A.C. Willis, A.F. Williams, and A.N. Barclay. 1990. High level expression in Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation variants. *J. Biol. Chem.* 265:10410.
50. Bebbington, C.R., and C.C.G. Hentchel. 1985. The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells. In *DNA Cloning: A Practical Approach*, Vol. III. D.M. Glover, editor. IRL Press Ltd., Oxford. 163 pp.
51. Ierino, F.L., M.D. Hulett, I.F.C. and P.M. Hogarth. 1993. Mapping epitopes of human FcγRII (CDw32) with monoclonal antibodies and recombinant receptors. *J. Immunol.* 150:1794.
52. Looney, R.J., G.N. Abraham, and C.L. Anderson. 1986. Human monocyttes and U937 cells bear two distinct Fc receptors for IgG. *J. Immunol.* 136:1641.
53. Pilkington, G.R., G.T.H. Lee, P.M. Michael, D.M. Garson, N. Kraft, R.C. Atkins, and D.G. Jose. 1986. Subclassification of leukaemia using monoclonal antibodies. In *Leukaemcy Typing II*. E.L. Reinherz et al., editors. Springer-Verlag, New York. 353 pp.
54. Hogarth, P.M., B.A. Houlden, S.E. Latham, M. Cherry, B.A. Taylor, and I.F.C. McKenzie. 1988. The mouse Ly-12.1 specificiy: genetic and biochemical relationship to Ly-1. *Immunogenetics.* 27:383.
55. Harlow, E., and D. Lane. 1988. Labelling antibodies. In *Antibodies: A Laboratory Manual*. Cold Spring Harbor Laborataries, Cold Spring Harbor, NY. 328 pp.
56. Hogarth, P.M., J. Edwards, I.F.C. McKenzie, J.W. Godling, and F.Y. Lieu. 1982. Monoclonal antibodies to the murine Ly-2.1 cell surface antigen. *Immunology.* 46:135.
57. Teh, J.-G., C. Thompson, and I.F.C. McKenzie. 1988. Production of monoclonal antibodies to serum antigens in colorectal carcinoma. *J. Immunol. Methods.* 110:101.
58. Parish, C.R., and J.A. Haywood. 1974. The lymphocyte surface. 1. Relation between Fc receptors, C'3 receptors and surface immunoglobulin. *Proc. R. Soc. Lond. (Ser. B. Biol. Sci.).* 187:47.
59. Tax, W.J.M., F.F.M. Hermes, H.W. Willems, P.J.A. Capel, and R.A.P. Koene. 1984. Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody induced T-cell proliferation. *J. Immunol.* 133:1185.
60. Tax, W.J.M., H.W. Willems, P.P.M. Reekers, P.J.A. Capel, and R.A.P. Koene. 1983. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigens on human T cells. *Nature (Lond.).* 304:445.
61. Sterling, K.J. 1951. The turnover rate of serum albumin in man as measured by 131I-tagged albumin. *J. Clin. Invest.* 30:1228.
62. Pfum, L.R., and M.L. Graeme. 1979. The Arthus reaction.
in rats, a possible test for anti-inflammatory and anti-rheumatic
drugs. Agents Actions. 9:184.
66. Yeh, C.G., H.C. Marsh, Jr., G.R. Carson, L. Berman, M.F.
Concino, S.M. Scesney, R.F. Keustner, R. Skibbens, K.A.
Donahue, and S.H. Ip. 1991. Recombinant soluble human com-
plement receptor type I inhibits inflammation in the reversed
passive Arthus reaction in rats. J. Immunol. 146:250.
67. Goldman, R.N., and J.S. Weinberg. 1985. Statistics: An In-
troduction. Prentice-Hall Inc., Englewood Cliffs, NJ. 468 pp.
68. Clark, M.R., S.B. Clarkson, P.A. Ory, N. Stollman, and I.M.
Goldstein. 1989. Molecular basis for a polymorphism involving
Fc receptor II on monocytes. J. Immunol. 143:1731.
69. Wärderdam, P.A.M., J.G.J. Van de Winkel, E.J. Gosselin, and
P.J.A. Capel. 1990. Molecular basis for a polymorphism of
human Fcγ receptor II (CD32). J. Exp Med. 172:19.
70. Tate, B.J., E. Witort, I.F.C. McKenzie, and P.M. Hogarth.
1992. Expression of the high responder/non-responder human
FcγRII. Analysis by PCR and transfection into FcR− COS
cells. Immunol. Cell. Biol. 70:79.
71. Lublin, D.M., R.C. Griffith, and J.P. Atkinson. 1986. Influence
of glycosylation on allelic and cell-specific Mr variation, receptor
processing, and ligand binding of the human complement
C3b/C4b receptor. J. Biol. Chem. 261:5736.
72. Yeh, P., D. Landais, M. Lemaitre, I. Maury, J.-Y. Crenne, J.
Bequart, A. Murry-Brelier, F. Boucher, G. Montay, R. Fleer,
et al. 1992. Design of yeast-secreted albumin derivatives for
human therapy: biological and antiviral properties of a serum
albumin-CD4 genetic conjugate. Proc. Natl. Acad. Sci. USA.
89:1904.
73. Katre, N.V., M.J. Krauf, and W.J. Laird. 1987. Chemical
modifications of a recombinant interleukin 2 by polyethylene
glycol increases its potency in the murine Meth A sarcoma
model. Proc. Natl. Acad. Sci. USA. 84:1487.
74. Moran, P., H. Beasley, A. Gorrell, E. Martin, P. Gribling, H.
Fuchs, N. Gillet, L.E. Burton, and I.W. Caras. 1992. Human
recombinant soluble decay accelerating factor inhibits comple-
ment activation in vitro and in vivo. J. Immunol. 149:1736.